GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » EV-to-Revenue

SNY (Sanofi) EV-to-Revenue : 2.95 (As of Oct. 31, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Sanofi EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Sanofi's enterprise value is $151,359 Mil. Sanofi's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $51,370 Mil. Therefore, Sanofi's EV-to-Revenue for today is 2.95.

The historical rank and industry rank for Sanofi's EV-to-Revenue or its related term are showing as below:

SNY' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.35   Med: 3.12   Max: 4.34
Current: 2.92

During the past 13 years, the highest EV-to-Revenue of Sanofi was 4.34. The lowest was 2.35. And the median was 3.12.

SNY's EV-to-Revenue is ranked worse than
56.93% of 989 companies
in the Drug Manufacturers industry
Industry Median: 2.42 vs SNY: 2.92

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-10-31), Sanofi's stock price is $52.90. Sanofi's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $20.46. Therefore, Sanofi's PS Ratio for today is 2.59.


Sanofi EV-to-Revenue Historical Data

The historical data trend for Sanofi's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi EV-to-Revenue Chart

Sanofi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.40 2.93 3.11 2.68 2.63

Sanofi Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2.68 - 2.63 -

Competitive Comparison of Sanofi's EV-to-Revenue

For the Drug Manufacturers - General subindustry, Sanofi's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sanofi's EV-to-Revenue falls into.



Sanofi EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Sanofi's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=151358.894/51370.11
=2.95

Sanofi's current Enterprise Value is $151,359 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sanofi's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $51,370 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sanofi  (NAS:SNY) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Sanofi's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=52.90/20.464
=2.59

Sanofi's share price for today is $52.90.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2024 was $20.46.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sanofi EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sanofi's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanofi Business Description

Address
46, avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sanofi Headlines

From GuruFocus

Q3 2023 Sanofi SA Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2022 Sanofi SA Earnings Call Transcript

By GuruFocus Research 02-09-2024

Sanofi SA's Dividend Analysis

By GuruFocus Research 05-08-2024

Q3 2022 Sanofi SA Earnings Call Transcript

By GuruFocus Research 02-09-2024

Sanofi SA at Citi BioPharma Conference Transcript

By GuruFocus Research 02-09-2024

Sanofi SA at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 02-09-2024